
Gilles Lemesle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3792812/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost–effectiveness and cost–utility analyses. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 194-202.	4.0	4
2	Utility and safety of coronary angiography in patients with acute infective endocarditis who required surgery. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 905-913.e19.	0.8	3
3	Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease. Diabetes and Metabolism, 2022, 48, 101265.	2.9	3
4	Haemodynamic support during high-risk percutaneous coronary intervention. Archives of Cardiovascular Diseases, 2022, 115, 109-109.	1.6	0
5	One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial. Circulation, 2022, 145, 486-488.	1.6	15
6	Clinical significance of myocardial work parameters after acute myocardial infarction. European Heart Journal Open, 2022, 2, .	2.3	6
7	On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Thrombosis and Haemostasis, 2021, 121, 923-930.	3.4	3
8	Acute Coronary Syndrome in the Era of SARS-CoV-2 Infection: A Registry of the French Group of Acute Cardiac Care. CJC Open, 2021, 3, 311-317.	1.5	12
9	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 287-294.	4.0	3
10	Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the <scp>REALITY</scp> trial. Clinical Cardiology, 2021, 44, 143-150.	1.8	8
11	Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia. JAMA - Journal of the American Medical Association, 2021, 325, 552.	7.4	137
12	IMPELLA® or Extracorporeal Membrane Oxygenation for Left Ventricular Dominant Refractory Cardiogenic Shock. Journal of Clinical Medicine, 2021, 10, 759.	2.4	12
13	Myocardial Infarction incidence during national lockdown in two French provinces unevenly affected by COVID-19 outbreak: An observational study. Lancet Regional Health - Europe, The, 2021, 2, 100030.	5.6	18
14	Feasibility and safety of transfemoral transcatheter aortic valve implantation performed with a percutaneous coronary intervention-like approach. Archives of Cardiovascular Diseases, 2021, 114, 537-549.	1.6	9
15	Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab. Cardiac Failure Review, 2021, 7, e09.	3.0	4
16	Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. New England Journal of Medicine, 2021, 385, 297-308.	27.0	172
17	Very long-term outcomes of older adults with stable coronary artery disease (from the CORONOR) Tj ETQq1 1	0.784314 r 0.7	gBT /Overloc
18	Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI. Journal of the	2.8	23

Percutaneous Myocardial Revascularization in Late-Pres American College of Cardiology, 2021, 78, 1291-1305.

2.8 23

#	Article	IF	CITATIONS
19	It's never too early to beat your low-density lipoprotein cholesterol. Archives of Cardiovascular Diseases, 2021, 114, 1-3.	1.6	1
20	Prinzmetal's angina presenting as ventricular tachycardia and sudden cardiac death. Coronary Artery Disease, 2021, 32, 599-600.	0.7	2
21	Management of antithrombotics in situations with a gap in evidence: A national French survey focusing on patients with coronary artery disease and atrial fibrillation. International Journal of Cardiology, 2021, , .	1.7	0
22	An unusual left anterior descending artery myocardial bridging. Journal of Cardiovascular Computed Tomography, 2020, 14, e78-e79.	1.3	0
23	Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 788-801.	1.0	7
24	Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme. European Heart Journal, 2020, 41, 858-866.	2.2	32
25	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet, The, 2020, 396, 1737-1744.	13.7	75
26	Real-Life Incident Atrial Fibrillation in Outpatients with Coronary Artery Disease. Journal of Clinical Medicine, 2020, 9, 2367.	2.4	4
27	Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure. Proteomics - Clinical Applications, 2020, 14, 2000035.	1.6	2
28	Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health, The, 2020, 5, e536-e542.	10.0	169
29	Secondary prevention and outcomes in outpatients with coronary artery disease, atrial fibrillation or heart failure: a focus on disease overlap. Open Heart, 2020, 7, e001165.	2.3	8
30	Association between rs4149056 variant in SLCO1B1 and early discontinuation of statin after acute myocardial infarction. Pharmacogenomics, 2020, 21, 163-172.	1.3	3
31	TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. American Heart Journal, 2020, 225, 19-26.	2.7	14
32	Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment. JACC: Cardiovascular Interventions, 2020, 13, 907-917.	2.9	31
33	Gender differences in clinical characteristics, medical management, risk factor control, and long-term outcome of patients with stable coronary artery disease: from the CORONOR registry. Panminerva Medica, 2020, 61, 432-438.	0.8	2
34	Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry. ESC Heart Failure, 2020, 7, 3821-3829.	3.1	3
35	Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015. American Heart Journal, 2019, 214, 97-106.	2.7	20
36	Letter by Bonello et al Regarding Article, "Early Versus Standard Care Invasive Examination and Treatment of Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: VERDICT Randomized Controlled Trial― Circulation, 2019, 139, e959-e960.	1.6	0

#	Article	IF	CITATIONS
37	Etiology and Prognosis of Cardiogenic Shock in a Secondary Center without Surgical Back-Up. Cardiology Research and Practice, 2019, 2019, 1-7.	1.1	3
38	Aspirin on Top of Anticoagulation in Patients With Concomitant Stable Coronary Artery Disease and Atrial Fibrillation. Circulation, 2019, 139, 617-619.	1.6	10
39	Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2019, 20, 295-304.	1.8	9
40	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. Platelets, 2019, 30, 105-111.	2.3	3
41	Temporal trends in clinical characteristics and management according to sex in patients with cardiogenic shock after acute myocardial infarction: The FAST-MI programme. Archives of Cardiovascular Diseases, 2018, 111, 555-563.	1.6	22
42	Early versus delayed invasive strategy for intermediate―and highâ€risk acute coronary syndromes managed without P2Y ₁₂ receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial. Clinical Cardiology, 2018, 41, 5-12.	1.8	6
43	Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5‥ear CORONOR Registry. Journal of the American Heart Association, 2018, 7, .	3.7	10
44	A consensus statement on lipid management after acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 532-543.	1.0	27
45	Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. Archives of Cardiovascular Diseases, 2018, 111, 634-643.	1.6	8
46	First Hospitalization for Heart Failure in Outpatients With Stable Coronary Artery Disease: Determinants, Role of Incident Myocardial Infarction, and Prognosis. Journal of Cardiac Failure, 2018, 24, 815-822.	1.7	24
47	Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease. Thrombosis and Haemostasis, 2018, 118, 1839-1846.	3.4	15
48	Incidence and determinants of cerebrovascular events in outpatients with stable coronary artery disease. European Stroke Journal, 2018, 3, 272-280.	5.5	7
49	Arterial Pulsatility and Circulating vonÂWillebrand Factor in Patients onÂMechanical CirculatoryÂSupport. Journal of the American College of Cardiology, 2018, 71, 2106-2118.	2.8	86
50	Elective Coronary Revascularization Procedures in Patients With StableÂCoronary Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 868-875.	2.9	7
51	Accuracy of cardiac magnetic resonance imaging to rule out significant coronary artery disease in patients with systolic heart failure of unknown aetiology: Single-centre experience and comprehensive meta-analysis. Archives of Cardiovascular Diseases, 2018, 111, 686-701.	1.6	5
52	Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction. Circulation: Heart Failure, 2018, 11, e004838.	3.9	21
53	Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?. Current Vascular Pharmacology, 2018, 16, 418-426.	1.7	4
54	Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 26-33.	1.0	17

#	Article	IF	CITATIONS
55	Angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: Prevalence, correlates, and prognostic impact (from the CORONOR) Tj ETQq1 1	. 0 .78.4 814 r	gBa ∣Overloo
56	Incident Myocardial Infarction and Very Late Stent Thrombosis in Outpatients WithÂStable Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 2149-2156.	2.8	35
57	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 198-213.	3.0	18
58	LONG-TERM OUTCOME WITH ORAL ANTICOAGULANTS WITH OR WITHOUT DUAL ANTIPLATELET THERAPY AFTER AMI: THE FAST-MI 2010 REGISTRY. Journal of the American College of Cardiology, 2017, 69, 207.	2.8	0
59	Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from) Tj ETQq	. 10.784314 1.6	4 rgBT /Over
60	Acute Myocardial Infarction. Circulation, 2017, 136, 1908-1919.	1.6	352
61	Vitamin K antagonists with or without longâ€ŧerm antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clinical Cardiology, 2017, 40, 932-939.	1.8	43
62	Effect of left ventricular systolic dysfunction on secondary medical prevention and clinical outcome in stable coronary artery disease patients. Archives of Cardiovascular Diseases, 2017, 110, 35-41.	1.6	4
63	Research and Therapeutic Nihilisms in Chronic Kidney Disease. JACC: Cardiovascular Interventions, 2017, 10, 2343-2344.	2.9	4
64	Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. International Journal of Cardiology, 2016, 216, 190-193.	1.7	6
65	Catheter tip erosion due to Rotablator burr: An unusual complication. Cardiovascular Revascularization Medicine, 2016, 17, 344-345.	0.8	0
66	Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). Cardiology, 2016, 134, 11-18.	1.4	8
67	Timing of Coronary Invasive Strategy inÂNon–ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes. JACC: Cardiovascular Interventions, 2016, 9, 2267-2276.	2.9	65
68	Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2016, 375, 335-344.	27.0	128
69	A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction. International Journal of Cardiology, 2016, 217, 109-121.	1.7	37
70	Effect of aspirin in addition to oral anticoagulants in stable coronary artery disease outpatients with an indication for anticoagulation. Panminerva Medica, 2016, 58, 271-285.	0.8	7
71	Practice Patterns for Outpatients With Stable Coronary Artery Disease: A Case Vignette-based Survey Among French Cardiologists. EBioMedicine, 2015, 2, 1662-1668.	6.1	5
72	Stent length as a potential indicator to select patients who may benefit from long-term dual antiplatelet therapy. Interventional Cardiology, 2015, 7, 419-426.	0.0	0

#	Article	IF	CITATIONS
73	Multimarker Proteomic Profiling for the Prediction of Cardiovascular Mortality in Patients with Chronic Heart Failure. PLoS ONE, 2015, 10, e0119265.	2.5	15
74	Secondary medical prevention and clinical outcome in coronary artery disease patients with a history of non-coronary vascular intervention: A report from the CORONOR investigators. European Journal of Preventive Cardiology, 2015, 22, 864-871.	1.8	7
75	Copeptin in acute coronary syndromes and heart failure management: State of the art and future directions. Archives of Cardiovascular Diseases, 2015, 108, 398-407.	1.6	25
76	Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease. Archives of Cardiovascular Diseases, 2015, 108, 340-346.	1.6	7
77	Dual antiplatelet therapy in patients with a long coronary artery lesion over 30mm: Determinants and impact on prognosis. Archives of Cardiovascular Diseases, 2015, 108, 235-243.	1.6	6
78	Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study. International Journal of Cardiology, 2015, 187, 502-507.	1.7	37
79	High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 931-942.	3.8	52
80	Dual antiplatelet therapy and non-cardiovascular mortality. Lancet, The, 2015, 385, 756-757.	13.7	3
81	Prognostic impact of ß-blocker use in patients with stable coronary artery disease. Heart, 2014, 100, 1757-1761.	2.9	29
82	Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results. Medical Devices: Evidence and Research, 2014, 7, 35.	0.8	9
83	Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure. Circulation Research, 2014, 114, 1569-1575.	4.5	542
84	Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding inÂOutpatients With Stable Coronary ArteryÂDisease. Journal of the American College of Cardiology, 2014, 64, 1430-1436.	2.8	91
85	Poor agreement between light transmission aggregometry, Verify Now P2Y12and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials. Platelets, 2014, 25, 499-505.	2.3	25
86	Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: Prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients) Tj ETQq0 0 0 rg[3T /@yøerloc	:k 160 Tf 50 21
87	A giant right coronary artery related to a small fistula to the coronary sinus. Cardiovascular Revascularization Medicine, 2014, 15, 121-124.	0.8	0
88	Impact of initial clinical presentation on clopidogrel low response. Archives of Cardiovascular Diseases, 2013, 106, 593-600.	1.6	1
89	Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 4921-4924.	1.7	3
90	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	1.7	160

#	Article	IF	CITATIONS
91	Biolimus-eluting stent with biodegradable polymer (Nobori®): an overview of recent clinical results, SORT OUT V and COMPARE II trials. Expert Review of Cardiovascular Therapy, 2013, 11, 1293-1296.	1.5	4
92	Serum MMP-8: A Novel Indicator of Left Ventricular Remodeling and Cardiac Outcome in Patients after Acute Myocardial Infarction. PLoS ONE, 2013, 8, e71280.	2.5	39
93	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	1.7	87
94	Use of Invasive Strategy in Non–ST-Segment Elevation Myocardial Infarction Is a Major Determinant of Improved Long-Term Survival. JACC: Cardiovascular Interventions, 2012, 5, 893-902.	2.9	71
95	Transcutaneous Aortic Valve Implantation Using the Left Carotid Access: Feasibility and Early Clinical Outcomes. Annals of Thoracic Surgery, 2012, 93, 1489-1494.	1.3	84
96	Incidence and predictors of microvascular dysfunction assessed by the index of microcirculatory resistance following primary PCI for ST-elevation myocardial infarction. International Journal of Cardiology, 2011, 146, 465-467.	1.7	7
97	The Presence of Apoptotic Bone Marrow Cells Impairs the Efficacy of Cardiac Cell Therapy. Cell Transplantation, 2011, 20, 1087-1097.	2.5	8
98	Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. American Journal of Cardiology, 2011, 108, 1710-1713.	1.6	34
99	Platelet reactivity in diabetic patients subjected to acute exercise stress test. Cardiovascular Revascularization Medicine, 2011, 12, 20-24.	0.8	3
100	Genotypic and Phenotypic Assessment of Platelet Function and Response to P2Y12 Antagonists. Current Cardiology Reports, 2011, 13, 439-450.	2.9	2
101	Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation: A Review of the Current Guidelines and Literature. Hospital Practice (1995), 2011, 39, 32-40.	1.0	11
102	Response to Letters Regarding Article, "Does Black Ethnicity Influence the Development of Stent Thrombosis in the Drug-Eluting Stent Era?― Circulation, 2011, 123, .	1.6	0
103	Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. EuroIntervention, 2011, 6, 1053-1059.	3.2	14
104	Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2010, 75, 86-92.	1.7	27
105	Does Black Ethnicity Influence the Development of Stent Thrombosis in the Drug-Eluting Stent Era?. Circulation, 2010, 122, 1085-1090.	1.6	46
106	Dosing Strategies for Antiplatelet Therapy in Percutaneous Coronary Intervention. Hospital Practice (1995), 2010, 38, 50-58.	1.0	2
107	Aortic valve implantation with the CoreValve ReValving System via left carotid artery access: First case report. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 928-929.	0.8	85
108	Long-Term Prognostic Value of Preprocedural C-Reactive Protein After Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 826-832.	1.6	27

#	Article	IF	CITATIONS
109	Clinical Profile, Treatment Assignment and Clinical Outcome of Patients With Severe Aortic Stenosis Not Eligible to Participate in a Clinical Trial of Percutaneous Aortic Valve Replacement. American Journal of Cardiology, 2010, 105, 857-861.	1.6	6
110	Prophylactic use of intra-aortic balloon pump for high-risk percutaneous coronary intervention: will the Impella LP 2.5 device show superiority in a clinical randomized study?. Cardiovascular Revascularization Medicine, 2010, 11, 91-97.	0.8	13
111	Impact of thrombus aspiration use and direct stenting on final myocardial blush score in patients presenting with ST-elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2010, 11, 149-154.	0.8	4
112	Should we screen for masked hypertension in patient with vascular disease?. Vascular Health and Risk Management, 2010, 6, 333.	2.3	4
113	Decline in platelet count in patients treated by percutaneous coronary intervention: definition, incidence, prognostic importance, and predictive factors. European Heart Journal, 2010, 31, 1079-1087.	2.2	43
114	Drug-Eluting Stents: Issues of Late Stent Thrombosis. Cardiology Clinics, 2010, 28, 97-105.	2.2	24
115	Thrombus aspiration for the treatment of definite stent thrombosis. Archives of Cardiovascular Diseases, 2010, 103, 33-38.	1.6	3
116	Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease. Archives of Cardiovascular Diseases, 2010, 103, 502-511.	1.6	27
117	Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thrombosis Research, 2010, 126, e147-e149.	1.7	37
118	Perioperative outcomes in reoperative cardiac surgery guided by cardiac multidetector computed tomographic angiography. American Heart Journal, 2010, 159, 301-306.	2.7	30
119	Unusual evolution of an aneurysm of the proximal left anterior descending coronary artery 15 years after a Simpson atherectomy. Archives of Cardiovascular Diseases, 2010, 103, 421-423.	1.6	0
120	Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. Expert Review of Cardiovascular Therapy, 2009, 7, 1525-1532.	1.5	1
121	Outcome Differences With the Use of Drug-Eluting Stents for the Treatment of In-Stent Restenosis of Bare-Metal Stents Versus Drug-Eluting Stents. American Journal of Cardiology, 2009, 103, 491-495.	1.6	90
122	Comparison of Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in Nonostial Proximal Left Anterior Descending Coronary Arteries. American Journal of Cardiology, 2009, 103, 496-500.	1.6	6
123	Racial Disparities in Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2009, 103, 653-658.	1.6	36
124	Prognostic Significance of Small Troponin I Rise After a Successful Elective Percutaneous Coronary Intervention of a Native Artery. American Journal of Cardiology, 2009, 103, 639-645.	1.6	36
125	Incidence, Predictors, and Outcome of New, Subsequent Lesions Treated With Percutaneous Coronary Intervention in Patients Presenting With Myocardial Infarction. American Journal of Cardiology, 2009, 103, 1189-1195.	1.6	17
126	Prognostic Value of Hemoglobin A1C Levels in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention With Stent Implantation. American Journal of Cardiology, 2009, 104, 41-45.	1.6	51

#	Article	IF	CITATIONS
127	Value of Blood Transfusion in Patients With a Blood Hematocrit of 24% to 30% After Percutaneous Coronary Intervention. American Journal of Cardiology, 2009, 104, 1069-1073.	1.6	11
128	Effect of Drug-Eluting Stents on Frequency of Repeat Revascularization in Patients With Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2009, 104, 1654-1659.	1.6	15
129	Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2009, 10, 144-150.	0.8	21
130	Prognostic value of the syntax score in patients undergoing coronary artery bypass grafting for threeâ€vessel coronary artery disease. Catheterization and Cardiovascular Interventions, 2009, 73, 612-617.	1.7	52
131	Paclitaxelâ€eluting balloon: From bench to bed. Catheterization and Cardiovascular Interventions, 2009, 73, 643-652.	1.7	58
132	Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. Catheterization and Cardiovascular Interventions, 2009, 73, 866-870.	1.7	6
133	Impact of bivalirudin on inâ€hospital bleeding and sixâ€month outcomes in octogenarians undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2009, 74, 428-435.	1.7	19
134	Impact of Bivalirudin Use on Outcomes in Nonagenarians Undergoing Percutaneous Coronary Intervention. Journal of Interventional Cardiology, 2009, 22, 61-67.	1.2	10
135	Clinical Manifestation and Prognosis of Early versus Late Stent Thrombosis of Drugâ€Eluting Stents. Journal of Interventional Cardiology, 2009, 22, 228-233.	1.2	10
136	Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. American Heart Journal, 2009, 157, 375-382.	2.7	45
137	Prognostic value of procedure-related myocardial infarction according to the universal definition of myocardial infarction in saphenous vein graft interventions. American Heart Journal, 2009, 157, 894-898.	2.7	12
138	The clinical significance of hematocrit values before and after percutaneous coronary intervention. American Heart Journal, 2009, 158, 1024-1030.	2.7	22
139	Intravascular ultrasound-guided percutaneous coronary interventions in contemporary practice. Archives of Cardiovascular Diseases, 2009, 102, 143-151.	1.6	12
140	Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: Comparison between drug-eluting stents and bare-metal stents. Archives of Cardiovascular Diseases, 2009, 102, 209-217.	1.6	24
141	Very late stent thrombosis after bare-metal stent implantation: case reports and review of the literature. Journal of Invasive Cardiology, 2009, 21, E27-32.	0.4	6
142	Impact of thrombus aspiration use for the treatment of stent thrombosis on early patient outcomes. Journal of Invasive Cardiology, 2009, 21, 210-4.	0.4	10
143	High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. Catheterization and Cardiovascular Interventions, 2008, 72, 470-478.	1.7	25
144	Vascular Brachytherapy for Patients with Drugâ€Eluting Stent Restenosis. Journal of Interventional Cardiology, 2008, 21, 528-534.	1.2	15

#	Article	IF	CITATIONS
145	Comparison of Safety, Efficacy, and Outcome of Successful Versus Unsuccessful Percutaneous Coronary Intervention in "True―Chronic Total Occlusions. American Journal of Cardiology, 2008, 102, 1175-1181.	1.6	64
146	Impact of a 600-mg Loading Dose of Clopidogrel on 30-Day Outcome in Unselected Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2008, 102, 1318-1322.	1.6	17
147	Impact of "Nuisance―Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. American Journal of Cardiology, 2008, 102, 1614-1617.	1.6	121
148	Stent thrombosis in 2008: Definition, predictors, prognosis and treatment. Archives of Cardiovascular Diseases, 2008, 101, 769-777.	1.6	49